Abstract:ID 90930 Poster Board 516 Text Parkinson's disease (PD) is a prevalent neurodegenerative condition characterized by degeneration of dopaminergic neurons in the substantia nigra of the midbrain. This results in bradykinesia, tremors, rigidity, and other motor and non-motor deficits. The prevalence of PD is increasing, in part, due to the aging population. Despite this growing burden, the development of effective therapies to halt disease progression remains an unmet need. This challenge is due to gaps in our understanding of the molecular mechanisms underlying the disease and deficiencies of preclinical models in recapitulating all aspects of the pathobiology of PD. Consequently, deepening our understanding of pathobiology and discovering druggable targets remain a research priority. Herein, we describe assay development and optimization of a high throughput phenotypic screen in the roundworm Caenorhabditis elegans for discovery of novel druggable targets and genetic influencers of neurodegeneration and neuroprotection. We utilized two transgenic C. elegans strains expressing human PD-linked genes—one with mutant (A53T) alpha-synuclein (SNCA) and the other expressing mutant (G2019S) leucine-rich repeat kinase 2 (LRRK2). These strains exclusively express the PD-related transgenes and green fluorescent protein (GFP) in their dopaminergic neurons, facilitating the tracking of neurodegeneration through measurable changes in the GFP fluorescence. Using laser cytometry and high content imaging with worms growing in liquid culture within 384-well plates, we assessed the health of the dopamine neurons via GFP intensity, number of neurons, and area of green objects. We observed a 30-50% and 75-85% decrease in GFP intensity in the SNCA and LRRK2 worms, respectively, by day seven compared to wild-type controls lacking the PD genes but expressing GFP exclusively in the dopaminergic neurons. We crossed the worms to RNAi hypersensitive backgrounds carrying eri-1, rrf-3, and eri-1;lin-15B mutations to overcome the typical resistance to neuronal RNAi knockdown in C. elegans . We observed a robust RNAi knockdown in the control and mutant worms with a 50-75% knockdown on day seven with RNAi against GFP, ama-1, ceh-43, and unc-62 compared to empty vector control. RNAi specifically engineered against the LRRK2 transgene slows neurodegeneration in the LRRK2 mutant worms. Additionally, we have identified selective LRRK2 kinase inhibitors that confer neuroprotection in the LRRK2-carrying worms with promising properties to serve as controls for high throughput molecular library screening. Further optimization studies are ongoing with the goal of conducting a screen for genes influencing neuroprotection in these models. Additionally, we plan to conduct a small molecule library screen for novel neuroprotective compounds using these PD models. These lines of inquiry may identify new molecules or potential druggable targets for novel therapeutics for influencing neurodegeneration and PD progression. Supported by the NINDS Intramural Research Program.

In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson’s Disease in Common Marmosets

An Accelerated Parkinson’s Disease Monkey Model Using AAV-α-synuclein Plus Poly(adp-Ribose)

Progressive Dopaminergic Alterations and Mitochondrial Abnormalities in LRRK2 G2019S Knock-in Mice

Mutating PINK1 gene by paired truncated sgRNA/Cas9-D10A in Cynomolgus Monkey

G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice

PINK1 gene mutation by pair truncated sgRNA/Cas9-D10A in cynomolgus monkeys

Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations

induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Adult Common Marmoset Fibroblasts.

Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice is Eliminated by Familial Parkinson's Disease Mutation G2019S

Co-editing PINK1 and DJ-1 genes via AAV-delivered CRISPR/Cas9 system in adult monkey brains elicits classic Parkinsonian phenotypes

Co-editing PINK1 and DJ-1 Genes Via Adeno-Associated Virus-Delivered CRISPR/Cas9 System in Adult Monkey Brain Elicits Classical Parkinsonian Phenotype

G2019S LRRK2 Mutation Enhances MPP+-Induced Inflammation of Human Induced Pluripotent Stem Cells-Differentiated Dopaminergic Neurons

Exploring Parkinson-associated kinases for CRISPR/Cas9-based gene editing: beyond alpha-synuclein

Production of a heterozygous exon skipping model of common marmosets using gene-editing technology

Neuroprotection in C. Elegans Parkinsons Disease Models: Discovering Therapeutic Insights via RNAi and Small Molecule High Throughput Screening

The LRRK2 kinase substrates RAB8a and RAB10 contribute complementary but distinct disease-relevant phenotypes in human neurons

Induction of core symptoms of autism spectrum disorder by in vivo CRISPR/Cas9-based gene editing in the brain of adolescent rhesus monkeys

Early molecular events of autosomal‐dominant Alzheimer's disease in marmosets with PSEN1 mutations

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease